Previous 10 | Next 10 |
BioMarin Announces Favorable Results from Global Phase 2 Study of VOXZOGO™ (vosoritide) for Injection in Infants and Young Children with Achondroplasia at The Endocrine Society Annual Meeting, ENDO 2022 (June 11-14), in Atlanta PR Newswire Improvement in Height Z-...
Halvorsen's 13F portfolio value decreased from $34.49B to $24.74B this quarter. The number of positions decreased from 107 to 56. Viking Global increased Amazon.com, Fortive, and International Flavors & Fragrances while dropping Humana, Coupa Software, and Twilio. The top thre...
Investors may want to pay attention to BioMarin Pharmaceutical (NASDAQ:BMRN) after Bristol Myers (NYSE:BMY) agreed to buy Turning Point Therapeutics for $4 billion in cash earlier. BioMarin rose 3.1%. The connection between Turning Point (NASDAQ:TPTX) and BioMarin (BMRN) is that Mar...
Commercial-stage biotech BioMarin Pharmaceutical (NASDAQ:BMRN) announced on Tuesday that the FDA requested additional data for its planned Biologics Licensing Application (BLA) for hemophilia A therapy valoctocogene roxaparvovec. An investigational gene therapy, valoctocogene roxaparvovec is ...
BioMarin Announces Durable Hemostatic Efficacy Maintained Over 6 years in Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A PR Newswire 95% Reduction in Mean Annualized Bleed Rate (ABR) and 96% Reduction in Mean Annual...
In a down market, you can pick up the same fundamentally robust companies at a fraction of their intrinsic value. As an orphan disease innovator, BioMarin is enjoying significant and substantial revenue increases from its approved assets. Nevertheless, the company is aggressively ...
Potential to receive FDA approval of beti-cel for beta-thalassemia and eli-cel for cerebral adrenoleukoodystrophy in 2022. FDA approvals of beti-cel and eli-cel would give bluebird bio the ability to receive Priority Review Vouchers which it could sell for upwards of over $100 million...
BioMarin Hires Pharmaceutical Industry Leaders in Marketing and Accounting to Fill Strategic Roles Supporting Company's Growth Plans PR Newswire Humaira Serajuddin Named to Newly Created Role of Senior Vice President, Chief Marketing Officer Erin Burkhart , Named...
BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress, May 8-11, 2022, Including Five Platform Presentations PR Newswire Ongoing Clinical Development Progra...
BioMarin to Participate in the BofA Securities 2022 Healthcare Conference, Thursday, May 12 at 8:40amPT/11:40amET PR Newswire SAN RAFAEL, Calif. , May 4, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques B...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander ...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...